A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
- Conditions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1149
- Registration Number
- NCT02921828
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
🇺🇸Local Institution - Japan, No City Provided, New Jersey, United States
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
- Conditions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 4626
- Registration Number
- NCT02921802
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
- Conditions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 84
- Registration Number
- NCT02921815
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 66
- Registration Number
- NCT02903069
- Locations
- 🇺🇸
Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States
🇺🇸Northwestern Center For Clinical Research, Chicago, Illinois, United States
🇺🇸John Wayne Cancer Center Outpatient Clinic, Santa Monica, California, United States
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
- Conditions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2504
- Registration Number
- NCT02902900
- Locations
- 🇫🇷
Centre Hospitalier General, Saint Germain En Laye, France
🇫🇷Centre Hospitalier H. Duffaut, Avignon Cedex 9, France
🇫🇷Centre Hospitalier Intercommunal Robert Ballanger, Aulnay Sous Bois, France
An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 209
- Registration Number
- NCT02891551
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT02875223
- Locations
- 🇮🇹
Local Institution - 201, Milano, Italy
🇯🇵Local Institution - 500, Kashiwa, Japan
🇯🇵Local Institution - 501, Chuo-ku, Tokyo, Japan
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT02859324
- Locations
- 🇺🇸
UCLA Division of Hematology Oncology, Los Angeles, California, United States
🇪🇸Hospital 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitario Vall D Hebron, Barcelona, Spain
A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 326
- Registration Number
- NCT02849444
- Locations
- 🇪🇸
Hospital Universitario Puerta del Mar, Cádiz, Andalucía, Spain
🇪🇸Hospital Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸Hospital del Mar, Barcelona, Cataluña, Spain
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 101
- Registration Number
- NCT02848001
- Locations
- 🇺🇸
Local Institution - 104, Hackensack, New Jersey, United States
🇨🇦Local Institution - 201, Toronto, Ontario, Canada
🇳🇴Local Institution - 701, Oslo, Norway